Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review.

摘要: The efficacy benefits of biphasic insulin aspart formulation (BIAsp 30) in patients with diabetes mellitus have been reported several studies. BIAsp 30 has shown to be more effective terms glycaemic control than standard human (BHI 30). In addition gauging the treatment clinical evidence provided, it is also important evaluate strength supporting therapeutic improvements offered by 30. this paper, we evaluated available data that relate use type 2 based on a comprehensive literature review. Selected publications provided relevant were obtained via search and from manufacturer, Novo Nordisk. These graded they using Oxford Centre for Evidence-Based Medicine (CEBM) system following categories: (i) twice-daily versus basal insulin; (ii) other treatments; (iii) once-daily use; (iv) thrice-daily (v) combination thiazolidinediones; (vi) comparison BHI A total identified graded. For majority categories (four out six), was given an overall CEBM grade (highest quality); two (twice-daily administration) B. most studies examined, (glycosylated haemoglobin [HbA1c] reduction, proportion achieving HbA1c target <6.5% or <7%, fasting blood glucose, glucose profile and/or prandial postprandial increments). some studies, further plasma infusion rates, C-peptide levels, mean serum fructosamine hyperlipidaemia, well-being, satisfaction quality life. Safety physical laboratory investigations assessment incidence adverse events, including, many reviewed, specific evaluation those events known associated antidiabetic treatment, hypoglycaemia weight gain. Strong better without increases major nocturnal hypoglycaemic episodes. Overall, gain minimal not significantly greater Thus, can confirm tolerability variety endpoints supported good body relating its different dosage regimens regimens.